Cagrilintide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic amylin analog for significant weight loss, studied alone and with semaglutide in the fixed combination CagriSema. Human weight-loss evidence is strong, but claims of gentler GI tolerability than GLP-1 agonists are speculative. Gastrointestinal effects hit 41 to 63 percent of patients, and a theoretical thyroid cancer risk with limited long-term safety data remain unresolved. It is not FDA-approved.
Read Full recordStudied uses & evidence
Studied uses(6)
Significant Weight Loss
HighThe phase 2 trial showed 6.0–10.8% weight loss from baseline versus 3.0% with placebo; the highest cagrilintide dose outperformed liraglutide.
Appetite and Satiety Regulation
MediumAppetite suppression is mechanism based, inferred from weight loss trials rather than directly measured in humans.
Improved GI Tolerability vs GLP-1 Agonists
LowREDEFINE 1 directly randomized participants to cagrilintide, semaglutide, their combination, or placebo.
Evidence limits
- Evidence Level
- Strong
Cagrilintide has been evaluated in multiple Phase 1, Phase 2, and Phase 3 randomized controlled trials. The Phase 2 dose-finding trial (n=706) demonstrated dose-dependent weight loss up to 10.8% with the 4.5 mg dose. A Phase 1b trial (n=96) confirmed acceptable safety when co-administered with semaglutide 2.4 mg, with no pharmacokinetic interference. A Phase 2 trial in type 2 diabetes (n=92) showed CagriSema achieved 15.6% weight loss and 2.2% HbA1c reduction. The REDEFINE Phase 3 program demonstrated approximately 20-23% weight loss with CagriSema vs placebo. A systematic review and meta-analysis of 3 RCTs (n=430) confirmed CagriSema provides 9% additional weight loss over semaglutide alone with an acceptable safety profile. Evidence quality is rated strong based on multiple well-designed RCTs, though longer-term safety data beyond 68 weeks is still needed.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of MTC
AbsolutePersonal/family history of MTC — semaglutide is contraindicated; cagrilintide has no approved prescribing label.
History of pancreatitis
HighPancreatitis risk requires monitoring. Patients with prior pancreatitis should discuss risks carefully.
Severe gastroparesis
HighAmylin analogs slow gastric emptying. Pramlintide (same class) is contraindicated in gastroparesis.
Hypoglycemia unawareness
HighWhen co-administered with insulin, amylin analogs significantly increase severe hypoglycemia risk.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
Risk summary(11)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation, abdominal pain) affecting 41-63% of patients at therapeutic doses
HighInjection site reactions including redness, swelling, and pain at the subcutaneous injection site
ModerateThe MTC contraindication belongs to semaglutide labeling; it is not an approved cagrilintide-specific contraindication.
TheoreticalSemaglutide is contraindicated in MEN2; cagrilintide-specific approved contraindications have not been established.
TheoreticalRisk of hypoglycemia when combined with insulin or insulin secretagogues (sulfonylureas)
ModerateMay exacerbate symptoms in patients with gastroparesis or delayed gastric emptying
ModerateNot evaluated in pregnant or lactating individuals; should be avoided unless clinically justified
ModerateCaution required in severe renal impairment (eGFR <30 mL/min/1.73 m2) due to insufficient safety data
LowLong-term safety data beyond 68 weeks is currently limited
ModeratePotential interaction with warfarin due to rapid weight loss affecting drug metabolism
TheoreticalHigher vomiting rates observed with CagriSema combination (OR 9.57) compared to semaglutide alone
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.